Celia Schiffer to Antineoplastic Agents
This is a "connection" page, showing publications Celia Schiffer has written about Antineoplastic Agents.
Connection Strength
0.368
-
Kurt Yilmaz N, Schiffer CA. Introduction: Drug Resistance. Chem Rev. 2021 03 24; 121(6):3235-3237.
Score: 0.120
-
Weiss RB, Peterson BL, Allen SL, Browning SM, Duggan DB, Schiffer CA. A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study. Invest New Drugs. 1994; 12(1):41-3.
Score: 0.072
-
Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8.
Score: 0.064
-
Straza MW, Paliwal S, Kovi RC, Rajeshkumar B, Trenh P, Parker D, Whalen GF, Lyle S, Schiffer CA, Grossman SR. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle. 2010 Sep 15; 9(18):3740-50.
Score: 0.058
-
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, Fran?ois C, Larson RS, Wiernik PH. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000 Jan 01; 95(1):90-5.
Score: 0.027
-
Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN. CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proc Natl Acad Sci U S A. 2017 10 31; 114(44):11751-11756.
Score: 0.024
-
Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988 Nov; 29(3):152-63.
Score: 0.003